title: [Polyoxidonium in the treatment of calculous pyelonephritis].
abstract: Efficacy of polyoxidonium was studied in combined therapy of urolithiasis complicated with secondary pyelonephritis. Of 60 patients with secondary pyelonephritis in urolithiasis, 30 received adjuvant polyoxidonium. Phospholipids and cholesterol in cytomembranes were defined with thin-layer chromatography. Humoral immunity was evaluated by the levels of IgA, IgM, IgG, hemolytic activity of the compliment system, the level of circulating immune complexes, activity of lysozyme. Concentrations of IL-1beta, TNF, IL-4, IL-6 were also estimated. Subpopulations of immunocompetent cells were tested on flow cytofluorimeter by immunofluorescence with monoclonal antibodies. Phagocytic component of the immune system was assessed by phagocytic activity of neutrophils, phagocytic count, NBT test. The trial demonstrates that polyoxidonium has a positive action on the disease course, an antiinflammatory, immunomodulating properties, suppresses peroxidation, promotes recovery of structural-functional characteristics of cellular membranes in patients with urolithiasis and secondary pyelonephritis. Polyoxidonium is recommended in secondary pyelonephritis and urolithiasis as adjuvant to basic therapy for anti-inflammatory, detoxication and immunomodulating effect.
authors.forename: N I
authors.initials: NI
authors.lastname: Kazeko
authors.forename: V A
authors.initials: VA
authors.lastname: Zhmurov
authors.forename: A A
authors.initials: AA
authors.lastname: Borovskiĭ
authors.forename: G Ia
authors.initials: GIa
authors.lastname: Lerner
authors.forename: I V
authors.initials: IV
authors.lastname: Katrenko
authors.forename: E N
authors.initials: EN
authors.lastname: Nechaĭ
authors.forename: P A
authors.initials: PA
authors.lastname: Shmelev
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000917:Antibody Formation / Q000187:drug effects*; D002462:Cell Membrane / Q000737:chemistry; D002784:Cholesterol / Q000032:analysis; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000097:blood; D008297:Male; D009930:Organic Chemicals / Q000627:therapeutic use; D010743:Phospholipids / Q000032:analysis; D011704:Pyelonephritis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D016896:Treatment Outcome; D014545:Urinary Calculi / Q000150:complications / Q000188:drug therapy* / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D007136:Immunoglobulins; D009930:Organic Chemicals; D010743:Phospholipids; C089921:polyoxydonium; D002784:Cholesterol